Monthly Archives: September 2016

Non-Small Cell Lung Cancer Treatment (PDQ)Health …

Posted: September 23, 2016 at 4:47 am

General Information About Non-Small Cell Lung Cancer (NSCLC)

NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants. Although NSCLCs are associated with cigarette smoke, adenocarcinomas may be found in patients who have never smoked. As a class, NSCLCs are relatively insensitive to chemotherapy and radiation therapy compared with SCLC. Patients with resectable disease may be cured by surgery or surgery followed by chemotherapy. Local control can be achieved with radiation therapy in a large number of patients with unresectable disease, but cure is seen only in a small number of patients. Patients with locally advanced unresectable disease may achieve long-term survival with radiation therapy combined with chemotherapy. Patients with advanced metastatic disease may achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and other supportive measures.

Estimated new cases and deaths from lung cancer (NSCLC and SCLC combined) in the United States in 2016:[1]

Lung cancer is the leading cause of cancer-related mortality in the United States.[1] The 5-year relative survival rate from 1995 to 2001 for patients with lung cancer was 15.7%. The 5-year relative survival rate varies markedly depending on the stage at diagnosis, from 49% to 16% to 2% for patients with local, regional, and distant-stage disease, respectively.[2]

NSCLC arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. The histological type of NSCLC correlates with site of origin, reflecting the variation in respiratory tract epithelium of the bronchi to alveoli. Squamous cell carcinoma usually starts near a central bronchus. Adenocarcinoma and bronchioloalveolar carcinoma usually originate in peripheral lung tissue.

Anatomy of the respiratory system.

Smoking-related lung carcinogenesis is a multistep process. Squamous cell carcinoma and adenocarcinoma have defined premalignant precursor lesions. Before becoming invasive, lung epithelium may undergo morphological changes that include the following:

Dysplasia and carcinoma in situ are considered the principal premalignant lesions because they are more likely to progress to invasive cancer and less likely to spontaneously regress.

In addition, after resection of a lung cancer, there is a 1% to 2% risk per patient per year that a second lung cancer will occur.[3]

NSCLC is a heterogeneous aggregate of histologies. The most common histologies include the following:

These histologies are often classified together because approaches to diagnosis, staging, prognosis, and treatment are similar.

Increasing age is the most important risk factor for most cancers. Other risk factors for lung cancer include:

The single most important risk factor for the development of lung cancer is smoking. For smokers, the risk for lung cancer is on average tenfold higher than in lifetime nonsmokers (defined as a person who has smoked <100 cigarettes in his or her lifetime). The risk increases with the quantity of cigarettes, duration of smoking, and starting age.

Smoking cessation results in a decrease in precancerous lesions and a reduction in the risk of developing lung cancer. Former smokers continue to have an elevated risk for lung cancer for years after quitting. Asbestos exposure may exert a synergistic effect of cigarette smoking on the lung cancer risk.[19]

A significant number of patients cured of their smoking-related lung cancer may develop a second malignancy. In the Lung Cancer Study Group trial of 907 patients with stage T1, N0 resected tumors, the rate was 1.8% per year for nonpulmonary second cancers and 1.6% per year for new lung cancers.[20] Other studies have reported even higher risks of second tumors in long-term survivors, including rates of 10% for second lung cancers and 20% for all second cancers.[21]

Because of the persistent risk of developing second lung cancers in former smokers, various chemoprevention strategies have been evaluated in randomized control trials. None of the phase III trials with the agents beta carotene, retinol, 13-cis-retinoic acid, [alpha]-tocopherol, N-acetylcysteine, or acetylsalicylic acid has demonstrated beneficial, reproducible results.[18,22-25][Level of evidence: 1iiA] Chemoprevention of second primary cancers of the upper aerodigestive tract is undergoing clinical evaluation in patients with early-stage lung cancer.

Refer to the PDQ summaries on Lung Cancer Prevention and Smoking in Cancer Care for more information.

In patients considered at high risk for developing lung cancer, the only screening modality for early detection that has been shown to alter mortality is low-dose helical computed tomography (CT) scanning.[26] Studies of lung cancer screening with chest radiography and sputum cytology have failed to demonstrate that screening lowers lung cancer mortality rates.

(Refer to the Screening by low-dose helical computed tomography subsection in the PDQ summary on Lung Cancer Screening for more information.)

Lung cancer may present with symptoms or be found incidentally on chest imaging. Symptoms and signs may result from the location of the primary local invasion or compression of adjacent thoracic structures, distant metastases, or paraneoplastic phenomena. The most common symptoms at presentation are worsening cough or chest pain. Other presenting symptoms include the following:

Symptoms may result from local invasion or compression of adjacent thoracic structures such as compression involving the esophagus causing dysphagia, compression involving the laryngeal nerves causing hoarseness, or compression involving the superior vena cava causing facial edema and distension of the superficial veins of the head and neck. Symptoms from distant metastases may also be present and include neurological defect or personality change from brain metastases or pain from bone metastases. Infrequently, patients may present with symptoms and signs of paraneoplastic diseases such as hypertrophic osteoarthropathy with digital clubbing or hypercalcemia from parathyroid hormone-related protein. Physical examination may identify enlarged supraclavicular lymphadenopathy, pleural effusion or lobar collapse, unresolved pneumonia, or signs of associated disease such as chronic obstructive pulmonary disease or pulmonary fibrosis.

Investigations of patients with suspected NSCLC focus on confirming the diagnosis and determining the extent of the disease. Treatment options for patients are determined by histology, stage, and general health and comorbidities of the patient.

The procedures used to determine the presence of cancer include the following:

Before a patient begins lung cancer treatment, an experienced lung cancer pathologist must review the pathologic material. This is critical because SCLC, which responds well to chemotherapy and is generally not treated surgically, can be confused on microscopic examination with NSCLC.[27] Immunohistochemistry and electron microscopy are invaluable techniques for diagnosis and subclassification, but most lung tumors can be classified by light microscopic criteria.

(Refer to the Staging Evaluation section of this summary for more information on tests and procedures used for staging.)

The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[28] In particular, subsets of adenocarcinoma now can be defined by specific mutations in genes encoding components of the epidermal growth factor receptor (EGFR) and downstream mitogen-activated protein kinases (MAPK) and phosphatidylinositol 3-kinases (PI3K) signaling pathways. These mutations may define mechanisms of drug sensitivity and primary or acquired resistance to kinase inhibitors.

Other genetic abnormalities of potential relevance to treatment decisions include translocations involving the anaplastic lymphoma kinase (ALK)-tyrosine kinase receptor, which are sensitive to ALK inhibitors, and amplification of MET (mesenchymal epithelial transition factor), which encodes the hepatocyte growth factor receptor. MET amplification has been associated with secondary resistance to EGFR tyrosine kinase inhibitors.

Multiple studies have attempted to identify the prognostic importance of a variety of clinicopathologic factors.[21,29-32] Factors that have correlated with adverse prognosis include the following:

For patients with inoperable disease, prognosis is adversely affected by poor performance status and weight loss of more than 10%. These patients have been excluded from clinical trials evaluating aggressive multimodality interventions.

In multiple retrospective analyses of clinical trial data, advanced age alone has not been shown to influence response or survival with therapy.[47]

Refer to the separate treatment sections for each stage of NSCLC in this summary for more information about prognosis.

Because treatment is not satisfactory for almost all patients with NSCLC, eligible patients should be considered for clinical trials. Information about ongoing clinical trials is available from the NCI website.

Other PDQ summaries containing information related to lung cancer include the following:

Malignant non-small cell epithelial tumors of the lung are classified by the World Health Organization (WHO)/International Association for the Study of Lung Cancer (IASLC). There are three main subtypes of non-small cell lung cancer (NSCLC), including the following:

There are numerous additional subtypes of decreasing frequency.[1]

Most squamous cell carcinomas of the lung are located centrally, in the larger bronchi of the lung. Squamous cell carcinomas are linked more strongly with smoking than other forms of NSCLC. The incidence of squamous cell carcinoma of the lung has been decreasing in recent years.

Adenocarcinoma is now the most common histologic subtype in many countries, and subclassification of adenocarcinoma is important. One of the biggest problems with lung adenocarcinomas is the frequent histologic heterogeneity. In fact, mixtures of adenocarcinoma histologic subtypes are more common than tumors consisting purely of a single pattern of acinar, papillary, bronchioloalveolar, and solid adenocarcinoma with mucin formation.

Criteria for the diagnosis of bronchioloalveolar carcinoma have varied widely in the past. The current WHO/IASLC definition is much more restrictive than that previously used by many pathologists because it is limited to only noninvasive tumors.

If stromal, vascular, or pleural invasion are identified in an adenocarcinoma that has an extensive bronchioloalveolar carcinoma component, the classification would be an adenocarcinoma of mixed subtype with predominant bronchioloalveolar pattern and a focal acinar, solid, or papillary pattern, depending on which pattern is seen in the invasive component. However, the future of bronchioloalveolar carcinoma as a distinct clinical entity is unclear; a multidisciplinary expert panel representing the IASLC, the American Thoracic Society, and the European Respiratory Society proposed a major revision of the classification of adenocarcinomas in 2011 that entails a reclassification of what was called bronchioloalveolar carcinoma into newly defined histologic subgroups.

The following variants of adenocarcinoma are recognized in the WHO/IASLC classification:

In addition to the general category of large cell carcinoma, several uncommon variants are recognized in the WHO/IASLC classification, including the following:

Basaloid carcinoma is also recognized as a variant of squamous cell carcinoma, and rarely, adenocarcinomas may have a basaloid pattern; however, in tumors without either of these features, they are regarded as a variant of large cell carcinoma.

LCNEC is recognized as a histologically high-grade non-small cell carcinoma. It has a very poor prognosis similar to that of small cell lung cancer (SCLC). Atypical carcinoid is recognized as an intermediate-grade neuroendocrine tumor with a prognosis that falls between typical carcinoid and high-grade SCLC and LCNEC.

Neuroendocrine differentiation can be demonstrated by immunohistochemistry or electron microscopy in 10% to 20% of common NSCLCs that do not have any neuroendocrine morphology. These tumors are not formally recognized within the WHO/IASLC classification scheme because the clinical and therapeutic significance of neuroendocrine differentiation in NSCLC is not firmly established. These tumors are referred to collectively as NSCLC with neuroendocrine differentiation.

This is a group of rare tumors. Spindle cell carcinomas and giant cell carcinomas comprise only 0.4% of all lung malignancies, and carcinosarcomas comprise only 0.1% of all lung malignancies. In addition, this group of tumors reflects a continuum in histologic heterogeneity as well as epithelial and mesenchymal differentiation. On the basis of clinical and molecular data, biphasic pulmonary blastoma is regarded as part of the spectrum of carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements.

The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[2] In particular, subsets of adenocarcinoma now can be defined by specific mutations in genes encoding components of the epidermal growth factor receptor (EGFR) and downstream mitogen-activated protein kinases (MAPK) and phosphatidylinositol 3-kinases (PI3K) signaling pathways. These mutations may define mechanisms of drug sensitivity and primary or acquired resistance to kinase inhibitors. Other mutations of potential relevance to treatment decisions include:

These mutations are mutually exclusive, except for those involving PI3KCA and BRAF mutations, EGFR mutations, or ALK translocations.[3,4]

EGFR and ALK mutations predominate in adenocarcinomas that develop in nonsmokers, and KRAS and BRAF mutations are more common in smokers or former smokers. EGFR mutations strongly predict the improved response rate and progression-free survival of EGFR inhibitors. In a set of 2,142 lung adenocarcinoma specimens from patients treated at Memorial Sloan Kettering Cancer Center, EGFR exon 19 deletions and L858R were found in 15% of tumors from former smokers (181 of 1,218; 95% confidence interval [CI], 1317), 6% from current smokers (20 of 344; 95% CI, 49), and 52% from never-smokers (302 of 580; 95% CI, 4856; P < .001 for ever- vs. never-smokers).[5]

Fusions of ALK with EML4 genes form translocation products that occur in ranges from 3% to 7% in unselected NSCLC and are responsive to pharmacological inhibition of ALK by agents such as crizotinib. Sensitizing fusions of ALK with other genes have also been reported. Other mutations that occur in less than 5% of NSCLC tumors include:

BRAF mutations are mutually exclusive of EGFR and KRAS mutations. Somatic mutations in MAP2K1 (also known as MEK) have been identified in 1% of NSCLC. MET oncogene encodes hepatocyte growth factor receptor. Amplification of this gene has been associated with secondary resistance to EGFR tyrosine kinase inhibitors.

In non-small cell lung cancer (NSCLC), the determination of stage is important in terms of therapeutic and prognostic implications. Careful initial diagnostic evaluation to define the location and to determine the extent of primary and metastatic tumor involvement is critical for the appropriate care of patients.

In general, symptoms, physical signs, laboratory findings, or perceived risk of distant metastasis lead to an evaluation for distant metastatic disease. Additional tests such as bone scans and computed tomography (CT)/magnetic resonance imaging (MRI) of the brain may be performed if initial assessments suggest metastases or if patients with stage III disease are under consideration for aggressive local and combined modality treatments.

Stage has a critical role in the selection of therapy. The stage of disease is based on a combination of clinical factors and pathological factors.[1] The distinction between clinical stage and pathological stage should be considered when evaluating reports of survival outcome.

Procedures used to determine staging include the following:

Procedures used to obtain tissue samples include bronchoscopy, mediastinoscopy, or anterior mediastinotomy. Pathological staging of NSCLC requires the following:

Prognostic and treatment decisions are based on some of the following factors:

At diagnosis, patients with NSCLC can be divided into the following three groups that reflect both the extent of the disease and the treatment approach:

Surgical staging of the mediastinum is considered standard if accurate evaluation of the nodal status is needed to determine therapy.

Accurate staging of the mediastinal lymph nodes provides important prognostic information.

Evidence (nodal status):

CT scanning is primarily used for determining the size of the tumor. The CT scan should extend inferiorly to include the liver and adrenal glands. MRI scans of the thorax and upper abdomen do not appear to yield advantages over CT scans.[4]

Evidence (CT scan):

The wider availability and use of FDG-PET scanning for staging has modified the approach to staging mediastinal lymph nodes and distant metastases.

Randomized trials evaluating the utility of FDG-PET scanning in potentially resectable NSCLC report conflicting results in terms of the relative reduction in the number of noncurative thoracotomies.

Although the current evidence is conflicting, FDG-PET scanning may improve results of early-stage lung cancer by identifying patients who have evidence of metastatic disease that is beyond the scope of surgical resection and that is not evident by standard preoperative staging procedures.

Evidence (FDG-PET scan):

Decision analyses demonstrate that FDG-PET scanning may reduce the overall costs of medical care by identifying patients with falsely negative CT scans in the mediastinum or otherwise undetected sites of metastases.[9-11] Studies concluded that the money saved by forgoing mediastinoscopy in FDG-PET-positive mediastinal lesions was not justified because of the unacceptably high number of false-positive results.[9-11] A randomized study found that the addition of FDG-PET scanning to conventional staging was associated with significantly fewer thoracotomies.[12] A second randomized trial evaluating the impact of FDG-PET scanning on clinical management found that FDG-PET scanning provided additional information regarding appropriate stage but did not lead to significantly fewer thoracotomies.[13]

The combination of CT imaging and FDG-PET scanning has greater sensitivity and specificity than CT imaging alone.[14]

Evidence (CT/FDG-PET scan):

For patients with clinically operable NSCLC, the recommendation is for a biopsy of mediastinal lymph nodes that were found to be larger than 1 cm in shortest transverse axis on chest CT scan or were found to be positive on FDG-PET scan. Negative FDG-PET scanning does not preclude biopsy of radiographically enlarged mediastinal lymph nodes. Mediastinoscopy is necessary for the detection of cancer in mediastinal lymph nodes when the results of the CT scan and FDG-PET scan do not corroborate each other.

Patients at risk for brain metastases may be staged with CT or MRI scans. One study randomly assigned 332 patients with potentially operable NSCLC and no neurological symptoms to brain CT or MRI imaging to detect occult brain metastasis before lung surgery. MRI showed a trend towards a higher preoperative detection rate than CT scan (P = .069), with an overall detection rate of approximately 7% from pretreatment to 12 months after surgery.[17] Patients with stage I or stage II disease had a detection rate of 4% (i.e., eight detections out of 200 patients); however, individuals with stage III disease had a detection rate of 11.4% (i.e., 15 detections out of 132 patients). The mean maximal diameter of the brain metastases was significantly smaller in the MRI group. Whether the improved detection rate of MRI translates into improved outcome remains unknown. Not all patients are able to tolerate MRI, and for these patients contrast-enhanced CT scan is a reasonable substitute.

Numerous nonrandomized, prospective, and retrospective studies have demonstrated that FDG-PET scanning seems to offer diagnostic advantages over conventional imaging in staging distant metastatic disease; however, standard FDG-PET scans have limitations. FDG-PET scans may not extend below the pelvis and may not detect bone metastases in the long bones of the lower extremities. Because the metabolic tracer used in FDG-PET scanning accumulates in the brain and urinary tract, FDG-PET scanning is not reliable for detection of metastases in these sites.[17]

The Revised International System for Staging Lung Cancer, based on information from a clinical database of more than 5,000 patients, was adopted in 2010 by the American Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer.[18,19] These revisions provide greater prognostic specificity for patient groups; however, the correlation between stage and prognosis predates the widespread availability of PET imaging.

Summary of Changes

This staging system is now recommended for the classification of both NSCLC and small cell lung carcinomas and for carcinoid tumors of the lung.[19]

The T (primary tumor) classifications have been redefined as follows:[19]

No changes have been made to the N (regional lymph nodes) classification. However, a new international lymph node map defining the anatomical boundaries for lymph node stations has been developed.

The M (distant metastasis) classifications have been redefined as follows:

The AJCC has designated staging by TNM classification to define NSCLC.[19]

In non-small cell lung cancer (NSCLC), results of standard treatment are poor except for the most localized cancers. All newly diagnosed patients with NSCLC are potential candidates for studies evaluating new forms of treatment.

Surgery is the most potentially curative therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure in a small number of patients and can provide palliation in most patients. Prophylactic cranial irradiation (PCI) may reduce the incidence of brain metastases, but there is no evidence of a survival benefit and the effect of PCI on quality of life is not known.[1,2] In patients with advanced-stage disease, chemotherapy or epidermal growth factor receptor (EGFR) kinase inhibitors offer modest improvements in median survival, though overall survival is poor.[3,4]

Chemotherapy has produced short-term improvement in disease-related symptoms in patients with advanced NSCLC. Several clinical trials have attempted to assess the impact of chemotherapy on tumor-related symptoms and quality of life. In total, these studies suggest that tumor-related symptoms may be controlled by chemotherapy without adversely affecting overall quality of life;[5,6] however, the impact of chemotherapy on quality of life requires more study. In general, medically fit elderly patients with good performance status obtain the same benefits from treatment as younger patients.

The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[7] In particular, genetic abnormalities in EGFR, MAPK, and PI3K signaling pathways in subsets of NSCLC may define mechanisms of drug sensitivity and primary or acquired resistance to kinase inhibitors. EGFR mutations strongly predict the improved response rate and progression-free survival of inhibitors of EGFR. Fusions of ALK with EML4 and other genes form translocation products that occur in ranges from 3% to 7% in unselected NSCLC and are responsive to pharmacological inhibition of ALK by agents such as crizotinib. MET oncogene encodes hepatocyte growth factor receptor. Amplification of this gene has been associated with secondary resistance to EGFR tyrosine kinase inhibitors.

The standard treatment options for each stage of NSCLC are presented in Table 11.

In addition to the standard treatment options presented in Table 11, treatment options under clinical evaluation include the following:

Several small series have reported that reduction in fluorodeoxyglucose-positron emission tomography (FDG-PET) after chemotherapy, radiation therapy, or chemoradiation therapy correlates with pathological complete response and favorable prognosis.[8-15] Studies have used different timing of assessments, FDG-PET parameters, and cutpoints to define FDG-PET response. Reduction in maximum standardized uptake value (SUV) of higher than 80% predicted for complete pathological response with a sensitivity of 90%, specificity of 100%, and accuracy of 96%.[16] Median survival after resection was greater for patients with tumor SUV values of lower than 4 (56 months vs. 19 months).[15] Patients with complete metabolic response following radiation therapy were reported to have median survivals of 31 months versus 11 months.[17]

FDG-PET may be more sensitive and specific than computed tomography (CT) scan in assessing response to induction therapy. Optimal timing of imaging remains to be defined; however, one study suggests that greater sensitivity and specificity of FDG-PET is achieved if repeat imaging is delayed until 30 days after radiation therapy.[16]

There is no clear role for routine posttreatment PET-CT scans.[18][Level of evidence: 3iiA]

Evidence (surveillance imaging after radiation therapy with or without chemotherapy):

Check the list of NCI-supported cancer clinical trials that are now accepting patients with non-small cell lung cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

In occult lung cancer, a diagnostic evaluation often includes chest x-ray and selective bronchoscopy with close follow-up (e.g., computed tomography scan), when needed, to define the site and nature of the primary tumor; tumors discovered in this fashion are generally early stage and curable by surgery.

After discovery of the primary tumor, treatment involves establishing the stage of the tumor. Therapy is identical to that recommended for other non-small cell lung cancer (NSCLC) patients with similar stage disease.

Standard treatment options for occult NSCLC include the following:

Check the list of NCI-supported cancer clinical trials that are now accepting patients with occult non-small cell lung cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

Stage 0 non-small cell lung cancer (NSCLC) frequently progresses to invasive cancer.[1-3] Patients may be offered surveillance bronchoscopies and, if lesions are detected, potentially curative therapies.

Standard treatment options for stage 0 NSCLC include the following:

Segmentectomy or wedge resection are used to preserve maximum normal pulmonary tissue since patients with stage 0 NSCLC are at a high risk for second lung cancers. Because these tumors are by definition noninvasive and incapable of metastasizing, they should be curable with surgical resection; however, such lesions, when identified, are often centrally located and may require a lobectomy.

Patients with central lesions may be candidates for curative endobronchial therapy. Endobronchial therapies that preserve lung function include photodynamic therapy, electrocautery, cryotherapy, and Nd-YAG laser therapy.[3-6]

Go here to read the rest:
Non-Small Cell Lung Cancer Treatment (PDQ)Health ...

Posted in Cell Therapy | Comments Off

Stem Cell Treatment Center Hawaii – Stem Cell Treatment …

Posted: September 21, 2016 at 10:49 am

The Hawaii Stem Cell Treatment Center is not offering stem cell therapy as a cure for any condition, disease or injury. No statements or treatments on this website have been evaluated or approved by the FDA. This website contains no medical advice. All statements and opinions provided by this website are provided for educational and informational purposes only and we do not diagnose or treat via this website or via telephone. The Hawaii Stem Cell Treatment Center is offering patient funded research to treat individual patients with their own autologous stem cells and is not involved in the use or manufacture of any investigational drugs.

The Hawaii Stem Cell Treatment Center does not claim that any applications or potential applications using these autologous stem cell treatments are approved by the FDA or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied. It is important for potential patients to do their own research based on the options that we present so that one can make an informed decision. Ay decision to participate in our patient funded experimental protocols is completely voluntary.

Originally posted here:
Stem Cell Treatment Center Hawaii - Stem Cell Treatment ...

Posted in Hawaii Stem Cells | Comments Off

Minnesota to resume umbilical cord blood donations …

Posted: September 20, 2016 at 7:45 pm

Donating umbilical cord blood a rich source of lifesaving stem cells hasnt been an option for new mothers in Minnesota for years.

But a new partnership between the University of Minnesota and the St. Louis Cord Blood Bank in Missouri could restore that chance and accelerate research at the U, a pioneering center for cord blood transplants and stem cell research.

Leaders of the two organizations are meeting Tuesday to finalize a deal allowing the university Medical Center to collect cord blood after childbirth and send it to St. Louis to be stored and matched to patients who need it.

Transplants of the regenerative stem cells in cord blood help fight cancers such as leukemia by killing the cancer cells and rebuilding immune systems that are wiped away by chemotherapy and radiation.

The absence of local donation hasnt hindered Minnesotans in receiving transplants from a national donor pool, but it has hampered the pace of research at the U, where Dr. John Wagner performed the worlds first cord blood transplant for leukemia in 1990.

And it is something of an embarrassment, considering the Us prominence in the specialty and the fact that Be The Match, the organization that matches cord blood to patients, is based in Minneapolis.

Fact is, this is the worlds largest cord blood transplant program, said Dr. Jeff McCullough, a U pathologist and specialist in transfusion medicine. To not even be collecting here for potential transplants? We should be able to do better than that.

Researchers benefit from local collections because they can receive cord blood units that are ruled unsuitable for transplant. Lacking that, Wagners team has had a limited supply of cord blood for research and has paid a premium to buy discarded units from other states.

U researchers are trying, among other things, to determine if cord blood medicine can move beyond rare cancers and become effective treatments for common diseases such as diabetes. They also are studying ways to coax cord blood stem cells to work faster, especially for cancer patients at risk of fatal infections while their immune systems recover.

Cord blood is the lingering blood in the umbilical cord and placenta after childbirth. Donation involves draining that blood after the cord is clamped and severed from the newborn.

While cord blood isnt the only source of stem cells, it has advantages over stem cells that are commonly obtained from adult bone marrow donors.

It saved my life

Phillip Englund received a stem cell transplant at the U Amplatz Childrens Hospital 80 days ago, at the ideal juncture of his chemotherapy and radiation, because a cord blood unit was immediately available.

On Friday, the 20-year-old from Grand Rapids, Minn., learned he is on track to go home after months in the Minneapolis hospital to fight leukemia, and that he can think about resuming college.

It saved my life, he said. As weird as it is [to receive stem cells from umbilical cord blood], it was what I needed.

The American Red Cross used to bank cord blood from hospitals in Minneapolis, Coon Rapids and Mankato but got out of the business six years ago.

McCullough directed the Red Cross bank at the time, and tried unsuccessfully to get the U to take it over. Other efforts to maintain cord blood banking in Minnesota fell apart when federal grants were steered toward states with greater demographic diversity, because of the need for cord blood from ethnic and racial minorities.

Starting a new bank would be difficult: It would have to collect hundreds of cord blood units at a cost of $2,000 per donation until it matched one to a patient and sold it to a transplant center.

Instead, existing banks are seeking to increase the national inventory by forming partnerships in other states.

Seeking a satellite donor site in Minnesota is a no-brainer, said Donna Regan, who directs the St. Louis bank.

We know they have the infrastructure and the interest and the motivation to collect cord blood.

Under a proposed deal, the St. Louis bank would bear the financial risks and rewards of collecting the cord blood for transplants, and the U would gain free access to discarded units for research.

Breakthroughs at the U

Among other innovations, U doctors pioneered the double-cord transplant by which two cord blood units are mixed for a single transplant. Individual units are sufficient for children, but often too small to treat adults.

They also are studying ways of broadening the match between donor and patient. Mismatched stem cells from bone marrow carry the risk of being rejected by patients after transplant a complication that can be fatal.

But U studies indicate that cord blood stem cells dont need to be as closely matched, and might even offer cancer-fighting benefits when mismatched.

That, ironically, could reduce the need for more cord blood donation, Wagner added, because it would increase the potential uses for every unit in the national inventory.

But other medical developments could have the effect of reducing supply. More mothers, for example, are asking that the clamping of their umbilical cords be delayed 30 to 60 seconds so more cord blood can transfuse into their newborns. The American College of Obstetrics and Gynecology hasnt endorsed the practice, but noted in a policy statement last December that it might offer health benefits. Delayed clamping, however, leaves less blood for donation often too little for transplants.

Demand for cord blood, meanwhile, could be on the rise especially if research by Wagner and his colleagues prove that cord blood is effective against a broad new range of diseases.

Read the rest here:
Minnesota to resume umbilical cord blood donations ...

Posted in Minnesota Stem Cells | Comments Off

University of Michigan Stem Cell Research | Experts List

Posted: September 20, 2016 at 7:45 pm

Experts List

As a leading center of biomedical research, the University of Michigan has many scientists who have been attracted to the promising new frontier of stem cells. They hope to build new understanding of basic biology and perhaps improved medical treatments.

Across a wide array of topics, from repairing facial injuries to attacking cancer, all types of stem cell research are being done at Michigan, using both adult and embryonic stem cells from humans and animals. To see some recent press releases on their important work, please see In the News.

Here are a few of the U-M researchers exploring stem cells:

Professor and Chair, Cell and Developmental Biology Director, Center for Organogenesis

Engels lab studies the embryonic development of mammals to determine how tissues and organs are generated, and how embryonic cells are instructed to become specialized cells. He is interested in learning how chemical signaling between cells works and how, when it goes wrong, cancers and other diseases can occur. These studies have led to surprising insights into the developmental origin of the central and peripheral nervous system, the kidney, the cardiovascular system and blood.

Engel Lab >

Professor of Neurology in the Medical School Director, A. Alfred Taubman Medical Research Institute Director, JDRF Center for the Study of Complications in Diabetes Director, ALS Clinic

As one of the nations leading biomedical researchers Feldman is conducting groundbreaking work in ALS (Lou Gehrigs Diseases) and other neurological diseases. One of the most exciting new approaches to treating ALS involves stem-cell technology. Injecting stem cells into the spinal cords of rats with ALS has shown great promise in arresting the disease.

A. Alfred Taubman Medical Research Institute >

Donald A. Kerr Collegiate Professor of Oral Pathology Chair of the Department of Biologic & Materials Sciences Associate Professor of Dentistry and Biomedical Engineering

Krebsbachs research focuses on bone growth and bone marrow with the goal of being able to help human tissue heal itself better and regrow missing or damaged areas. He is currently studying how human embryonic stem cells differentiate into bone tissue, using both cell cultures and biomaterial scaffolds in animal models. His work also compares the activity of embryonic stem cells to adult stem cells. His long-term goal is to understand the signals that specify bone cell differentiation of hES cells and work towards some day being able to grow replacement bone.

Krebsbach Lab > Video Clip >

Assistant Professor, Center for Stem Cell Biology at the Life Sciences Institute Assistant Professor of Hematology-Oncology in the Medical School

Maillard investigates the signals regulating the development and function of blood-forming stem cells. He is studying how these cells are supported in fetal hematopoietic organs, such as the fetal liver, the main site of blood development during fetal life before migration of blood-forming stem cells into the bone marrow to improve or enhance their function after transplantation. In addition, it might provide insights into the function of stem cells in other contexts, including in cancerous tissues.

Associate Professor of Neurology in the Medical School Acting Director, Epilepsy Research Program

Dr. Parents research has focused for a decade on the role of adult stem cells in epilepsy and stroke. His laboratory, working with the Michigan Center for Human Embryonic Stem Cell Research at U-M, is attempting to repair stroke damage by transplanting neural progenitor cells derived from embryonic stem cells.

Neurodevelopment and Regeneration Laboratory >

Director, Michigan Center for Human Embryonic Stem Cell Research Professor of Cell and Developmental Biology

OSheas lab is focused on the cell-to-cell communication that occurs during formation of the nervous system. In particular, her group is interested in a protein, thrombospondin, that appears to be telling new nerve cells to migrate in specific ways to form parts of the brain. Embryonic stem cells are being used to study patterns of gene expression during formation of the retina in animal models.

She also heads the Michigan Center for hES Cell Research, which is an NIH-funded central resource for the U-M campus that helps researchers from many labs culture and work with human embryonic stem cell lines that are on the approved list for NIH-funding.

Michigan Center for Human Embryonic Stem Cell Research > OShea Lab > Video Clip >

Director of the MStem Cell Laboratories Professor of Ob/Gyn, Urology, and Molecular and Integrated Physiology

Dr. Smiths research in stem cell biology and derivation of new human embryonic stem cells incorporates over 20 years of: i) experience directing clinical embryology laboratories for treatments of infertility and/or preserving fertility; ii) investigating intracellular regulation of chromatin remodeling in oocytes and molecular regulators of embryo development; iii) integrating novel technologies developed in chemical and biomedical engineering, material sciences, and physics into basic and applied studies of gametes, embryos, and embryonic stem cells. Collectively, these skills and investigations result in translating basic discoveries into solutions for current practical short-comings of human embryonic stem cell isolation, culture, differentiation, and establishment of model systems for human diseases.

Gary Smiths profile >

Director, University of Michigan Comprehensive Cancer Center Professor of Internal Medicine

Dr. Wicha is at the forefront of research into cancer stem cells, the small number of cells within a tumor that are capable of fueling the tumors growth. His team was first to identify stem cells in a solid tumor, finding them in breast cancer. Recent research suggests cancer stem cells share some basic elements with embryonic stem cells, as well as with normal adult stem cells. Thus, in order to understand how cancer stem cells are regulated, scientists have to study and understand how these pathways work in embryonic stem cells. By studying embryonic stem cells, we can accelerate efforts to find a cure for cancer.

Press release on stem cells in breast cancer > Comprehensive Cancer Center >

Research Assistant Professor, Center for Stem Cell Biology, Life Sciences Institute Assistant Professor of Cell and Developmental Biology, Medical School

Yamashita is elucidating the process of stem cell division and its role in the age-related decline in organ repair and in the onset of some cancers and other proliferative disorders. She studies the division of stem cells to establish which ones go on to replace differentiated cells and which ones maintain the pool of stem cells for future division. Yamashita won a prestigious MacArthur Fellowship in 2011.

Yamashita Lab >

See the rest here:
University of Michigan Stem Cell Research | Experts List

Posted in Michigan Stem Cells | Comments Off

Stem Cells for Orthopedics Missouri & Florida

Posted: September 18, 2016 at 2:48 pm

Orthopedic injuries can happen to anyone. No matter how old you are or how active your lifestyle is, getting hurt will quickly sideline you. As you age, you become even more vulnerable to arthritis and fractures. It is important to keep yourself strong and healthy, and if you get hurt, seek medical attention from a qualified orthopedic doctor as soon as possible.

Blue Tail Medical Group uses innovative methods for treating orthopedic conditions and injuries using regenerative therapies with stem cellsand platelet-rich plasma.

For many patients, stem cell therapy can reduce or eliminate the need for surgery and accelerate the healing process. Stem cell therapy can also provide long-lasting pain relief. Conditions treated range from basic sprains and strainsto degenerative arthritisand back pain.

From head to toe, some common orthopedic conditions we treat with stem cells include:

Visit our patient education libraryto learn more about these conditions.

In addition to stem cells, blood platelets (PRP) can also be administered in a super concentrated injection to stimulate the bodys natural healing process. The regenerative healing power of these therapies is why they are collectively referred to as regenerative medicine.

Using stem cells for orthopedics is a relatively new concept. Many physicians lack the necessary training and experience to offer this cutting-edge therapy to their patients.

Patients from across the US seek treatment at Blue Tail Medical Group. As experts in regenerative medicineour Missouri-based orthopedic doctors have trained other doctors on stem cell therapy procedures. Our doctors also present at conferences all over the world, and in the United States on a monthly basis, earning national recognition as leaders in orthopedic regenerative medicine.

Learn more:

Blue Tail Medical Groupis proud to offer this revolutionary technology for anyone who believes stem cell therapy can help them. Our treatment centersare located in St. Louis and Columbia, Missouri, and Naples, Florida.

See more here:
Stem Cells for Orthopedics Missouri & Florida

Posted in Missouri Stem Cells | Comments Off

Stem Cells Quotes – Notable Quotes

Posted: September 18, 2016 at 12:48 am

quotations about stem cell research

While we must devote enormous energy to conquering disease, it is equally important that we pay attention to the moral concerns raised by the new frontier of human embryo stem cell research. Even the most noble ends do not justify any means.

GEORGE W. BUSH, speech, August 9, 2001

3 likes

Tags: George W. Bush

In the beginning there is the stem cell; it is the origin of an organism's life. It is a single cell that can give rise to progeny that differentiate into any of the specialized cells of embryonic or adult tissues.

STEWART SELL, Stem Cells Handbook

2 likes

Tags: Stewart Sell

The best that can be said about embryonic stem cell research is that it is scientific exploration into the potential benefits of killing human beings.

TOM DELAY, Washington Post, May 25, 2005

1 likes

Tags: Tom Delay

My entire political career, I voted pro-life, and that is exactly why I favor the stem cell initiative. I believe in saving human life. I want cures to be found.

JOHN DANFORTH, TV add sponsored by the Missouri Coalition for Lifesaving Cures, November 2005

1 likes

Embryonic stem cell research is at the leading edge of a series of moral hazards.

GEORGE W. BUSH, Address to the Nation on Stem Cell Research, August 9, 2001

1 likes

Researchers and biotech executives foresee the day when the effects of many catastrophic diseases can be reversed. The damaged brains of Alzheimer's disease patients may be restored. Severed spinal cords may be rejoined. Damaged organs may be rebuilt. Stem cells provide hope that this dream will become a reality.

GEORGE WOLFF, The Biotech Investor's Bible

0 likes

Tags: George Wolff

And now science has presented us with a hope called stem cell research, which may provide our scientists with many answers that have for so long been beyond our grasp. I don't see how we can turn our backs on this. There are so many diseases that can be cured or at least helped. We've lost so much time already. I can't bear to lose any more.

NANCY REAGAN, speech at Juvenile Diabetes Research Foundation event, May 8, 2004

0 likes

Tags: Nancy Reagan

Ethical judgments about the use of embryonic stem cells in research and therapies flow from the status accorded to the embryo. Those who feel that an embryo is a human being, or should be treated as one because it has the potential to become a person, contend that it is unethical to do anything to an embryo that could not be done to a person. At the opposite end of the spectrum, some people have expressed the view that the embryo is nothing more than a ball of cells that can be treated in a manner similar to tissues used in transplantation.

STEVE USDIN, introduction, Human Embryonic Stem Cells

0 likes

Tags: Steve Usdin

I think we can do ethically guided embryonic stem cell research. We have 100,000 to 200,000 embryos that are frozen in nitrogen today from fertility clinics. These weren't taken from abortion or something like that. They're from a fertility clinic, and they're either going to be destroyed or left frozen. And I believe if we have the option, which scientists tell us we do, of curing Parkinson's, curing diabetes, curing, you know, some kind of a ... you know, paraplegic or quadriplegic or, you know, a spinal cord injury -- anything -- that's the nature of the human spirit. I think it is respecting life to reach for that cure.

JOHN KERRY, presidential debate, October 8, 2004

0 likes

Tags: John Kerry

Nuclear transfer technology, which allows you to create stem cells that are genetically identical to a particular patient, may be ... necessary in order to get the full value out of embryonic stem cells. This is the matter of taking the nucleus from a skin cell, putting it in a hollowed-out egg cell in a dish and growing it to the point where you can take stem cells out of it. It never enters a womb. Sperm and egg never meet. There's no pregnancy and yet the opponents of this research continue to cast this in terms of these are little tiny lives. In fact, these are specks smaller than a grain of sand in which we can derive stem cells that could have vast scientific and medical benefit.

DANIEL PERRY, PBS Online NewsHour, October 11, 2004

0 likes

Tags: Daniel Perry

I am pro-life. I believe human life begins at conception. I also believe that embryonic stem cell research should be encouraged and supported.

BILL FRIST, speech, July 29, 2005

0 likes

Tags: Bill Frist

As you know, Ronnie recently celebrated his ninetieth birthday. In earlier times, we would have been able to share our mutual pride in a life filled with wonderful memories. Now, while I can draw strength from these memories, I do it alone as Ronnie struggles in a world unknown to me or the scientists who devote their lives to Alzheimer's research. Because of this, I am determined to do what I can to save others from this pain and anguish. I'm writing, therefore, to ask your help in supporting what appears to be the most promising path to a cure -- stem cell research.

NANCY REAGAN, letter to George W. Bush, April 11, 2001

0 likes

Stem cells are like toenail clippings with a better career plan.

SCOTT ADAMS, Stick to Drawing Comics, Monkey Brain!

0 likes

Tags: Scott Adams

My point is, and our point as a community, is we have a very good and supportable conclusion that a vast majority of people in this country are in favor of science playing a leading role in making changes in the future and believe in embryonic stem cell research. So we're just saying, know that we have prayed on it, too, and we have thought about it, and we are good people, and we are family people, and we are people that take this very seriously, and we're as concerned as you are. And we've decided that we would like to take this step and to do it with caution and to do it with oversight and to do it with the strictest adherence to ethics and all of the principles this country stands for. But, allow us to do that without infusing the conversation with inflammatory rhetoric and name-calling and fear-mongering. It doesn't help.

MICHAEL J. FOX, ABC interview, October 29, 2006

0 likes

Tags: Michael J. Fox

At this moment, the full promise of stem cell research remains unknown, and it should not be overstated. But scientists believe these tiny cells may have the potential to help us understand, and possibly cure, some of our most devastating diseases and conditions. To regenerate a severed spinal cord and lift someone from a wheelchair. To spur insulin production and spare a child from a lifetime of needles. To treat Parkinson's, cancer, heart disease and others that affect millions of Americans and the people who love them. But that potential will not reveal itself on its own. Medical miracles do not happen simply by accident. They result from painstaking and costly research -- from years of lonely trial and error, much of which never bears fruit -- and from a government willing to support that work.

BARACK OBAMA, remarks at signing of Stem Cell Executive Order and Scientific Integrity Presidential Memorandum, March 9, 2009

0 likes

Tags: Barack Obama

Wise public policy concerning embryonic stem cell research must attend to three important -- sometimes competing -- responsibilities: to seek scientific knowledge and cures for terrible diseases, to protect human life in all its vulnerable stages, and to respect the diverse yet deeply held moral views of the American people.

LEON R. KASS, "Playing Politics With the Sick", Washington Post, October 8, 2004

0 likes

The supporters of embryo-destructive research want to cross a great moral divide. They are seeking not only to destroy human life made in God's image but also to manufacture life made in man's image.

CHUCK COLSON, "The Veto: Should We Cross the Great Moral Divide?", Free Republic, July 21, 2006

0 likes

Today, with the Executive Order I am about to sign, we will bring the change that so many scientists and researchers; doctors and innovators; patients and loved ones have hoped for, and fought for, these past eight years: we will lift the ban on federal funding for promising embryonic stem cell research. We will vigorously support scientists who pursue this research. And we will aim for America to lead the world in the discoveries it one day may yield.

BARACK OBAMA, remarks at signing of Stem Cell Executive Order and Scientific Integrity Presidential Memorandum, March 9, 2009

0 likes

The bottom line is that there are 400,000 frozen embryos in the United States, and a large percentage of those are going to be thrown out. Regardless of what you think the moral status of those embryos is, it makes sense to me that it's a better moral decision to use them to help people than just to throw them out. It's a very complex issue, but to me it boils down to that one thing. If you really explain what's happening -- that these frozen embryos are ultimately going to be thrown out -- almost everybody except those that have to keep to some kind of party line will say, "What's the problem with this? We should go forward with this."

JAMES THOMSON, "Stem cell pioneer does a reality check", NBC News, June 25, 2005

0 likes

While I understand the passion and the conviction of those for whom the blastocyst is a person from the moment of fertilization, I do not believe this, and it is [a] matter of faith for me as well. My passion and my conviction are toward the suffering of the one I see in need, ill or wounded.

LAURIE ZOLOTH, congressional testimony to the Senate Subcommittee on Science, Technology and Space, September 29, 2004

0 likes

Read the original here:
Stem Cells Quotes - Notable Quotes

Posted in Missouri Stem Cells | Comments Off

Cells Harvested From Human Urine Used to Make Stem Cells

Posted: September 18, 2016 at 12:45 am

Skip Article Header. Skip to: Start of Article. Neural progenitor cells derived from human urine cells. Image: Lihui Wang, Guangjin Pan and Duanqing Pei

By Liat Clark, Wired UK

Biologists in China have published a study detailing how they transformed common cells found in human urine into neural stem cells that can be used to create neurons and glial brain cells. The find holds huge potential for the rapid testing and development of new treatments for neurodegenerative disorders.

[partner id=wireduk align=right]The team, from the Guangzhou Institute of Biomedicine and Health, had announced in 2011 that it had successfully reprogrammed skin-like cells from the kidneys, found in urine, into induced pluripotent stem (iPS) cells. These iPS cells can be tweaked to become pretty much any human cell in the body; however the traditional technique prompting this transformation inserting pluripotent genes into the blanket cells via a genetically engineered retrovirus has its flaws. It seems the presence of the retrovirus leads to a destabilisation of the genome, rendering it unpredictable, susceptible to mutations and thus a liability.

Stem cell biologist Duanqing Pei and his team opted for another route, that they claim presents a safer, faster alternative. Having extracted kidney epithelial cells from the urine of three donors aged 10, 25 and 37, the team used vectors a type of DNA molecule useful in transporting genetic information from cell to cell to transport the information without having to integrate the new genes into the chromosome of the kidney cell, something that is presumed to be partly to blame for the aforementioned mutations.

In one experiment the pluripotent stem cells formed in Petri dishes after 12 days, which is about half the time it normally takes for them to form. These cultured cells soon took on the shape of neural rosettes and were deemed to be neural progenitor cells a precursor to a fully blown neural cell. Eventually these neural progenitor cells were cultured to become neurons and astrocyte and oligodendrocyte glial cells

Though the team did not definitively prove that the cells would have less mutations in the long run, it did suggest the method could provide a good alternative to using embryonic stem cells to build new neurons. In a 2007 study, when the embryonic stem cells began their transformation into neurons and were transplanted into the brains of rats suffering from an equivalent to Parkinsons, they began to divide too quickly and tumours formed. This time around, however, when the neurons and astrocytes were transplanted into rat brains they appeared to still be thriving a month later, with no signs of abnormal cell division or tumour formation.

The technique is extremely promising for several reasons. For one, the material is readily available and no invasive extraction is necessary. We work on childhood disorders, commented University of Connecticut Health Centre geneticist Marc Lalande, not involved in the study, in Nature, and its easier to get a child to give a urine sample than to prick them for blood.

Its also far better to be able to develop a cell derived from an individuals own cells they are less likely to prompt an immune response and rejection, which could be the case when using embryonic or umbilical cord stem cells to make iPS cells. The fact that it bypasses the ethical questions of using embryonic cells, and appears to take half the time to develop also provides researchers with a faster, more efficient way to help combat neurological diseases such as Alzheimers and Parkinsons. And with millions suffering from these degenerative disorders worldwide, anything that can speed up research will be of huge benefit.

Source: Wired.co.uk

Go here to see the original:
Cells Harvested From Human Urine Used to Make Stem Cells

Posted in Connecticut Stem Cells | Comments Off

Euro Biotechnology Congress

Posted: September 18, 2016 at 12:44 am

Track 1:Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs.Pharmaceutical Biotechnologyis an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs,diagnosticagents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes inhealthcarepractices and a significant contribution to the development of national economy.Biopharmaceuticalsconsists of large biological molecules which areproteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.

RelatedBiotechnology Conferences

Track 2:Biotechnology in Health Care

Biotechnology in health care represents the complex of modern biological approaches in the field of healthcare research and industry. Healthcare Biotechnology methods are used primarily in pharmaceutical industry and modern clinical diagnostics. The research training in this domain is programmed for the candidates intending to develop their careers in scientific-research institutions, clinical anddiagnostic laboratories, analytical services,pharmacologicalandpharmaceutical companies, etc. For the first time in the history of human healthcare, biotechnology is enabling the development and manufacturing of therapies for a number of rare diseases with a genetic origin. Although individually rare, collectively thesediseasesaffect some 20-30 million individuals and their families with 70-80% having a genetic component requiring biotechnology as part of the solution.

RelatedBiotechnology Conferences

Track 3:Food Biotechnology

Food biotechnology is a process scientists use to enhance the production,nutritional value, safety, and taste of foods. It can also benefit the environment by improving crops so that they need fewerpesticides. The concept is not new: For centuries farmers have selectively bred plants to pass on desirable qualities. For example, our ancestors began by replanting only corn seeds from the highest yielding and best tasting corn they grew each year. This process selected desirable genes and fixed them by growing the seeds of the selected crop year after year. The result: the golden, deliciously sweet product we now enjoy. Modernfood biotechnologyis a refined version of this same process. Today, scientists obtain desired traits by adding or removing plant genes. This process is called genetic engineering or recombinant DNA technology. It yields foods that are flavorful, contain more vitamins and minerals, and absorb less fat when cooked, and gives us crops that are more resistant to pests and insects. Food biotechnology holds great promise for the future. Soon, fruits and vegetables may be made to resist drought. We may remove allergens from foods such as nuts. Scientists may develop plants that absorb nitrogen more efficiently and need lessfertilizer. The benefits are nearly limitless!

RelatedBiotechnology Conferences

3rdGlobal Food Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;BiologicallyActive Compounds inFood, October 15-16 2015 Lodz, Poland; World Conference on InnovativeAnimal NutritionandFeeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood ScienceandBiotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference onAgricultural Science,Biotechnology,FoodandAnimal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia; International Conference of Eco-friendlyApplied BiologicalControl ofAgricultural PestsandPhytopathogens, 19 -22 October 2015, Cairo, Egypt;Food Structures,DigestionandHealth3rd International Conference, 28-30 October, Wellington, New Zealand; Conference ofCereal BiotechnologyandBreeding, November 2-4, 2015, Berlin, Germany; AdvancedWater TreatmentforFood & Beverage, November 3-4, 2015 Amsterdam, Netherlands.

Track 4:Industrial and Microbial Biotechnology

Industrial or white biotechnology uses enzymes and micro-organisms to make biobased products in sectors such as chemicals,food and feed, detergents, paper and pulp, textiles andbioenergy. The application of industrial biotechnology has been proven to make significant contributions towards mitigating the impacts of climate change in these and other sectors. In addition to environmental benefits, biotechnology can improve industrys performance and product value and, as the technology develops and matures,white biotechnologywill yield more and more viable solutions for our environment. These innovative solutions bring added benefits for both our climate and our economy.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; GlobalBiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track 5:Nanobiotechnology

Nanobiotechnologyis beginning to allow scientists, engineers, and physicians to work at the cellular and molecular levels to produce major benefits to life sciences and healthcare. In the next century, the emerging field of nanotechnology will lead to new biotechnology based industries and novel approaches in medicine. Nanobiotechnology is that branch of nanotechnology that deals with biological and biochemical applications or uses. Nanobiotechnology often studies existing elements of living organisms and nature to fabricate newnano-devices. Generally, nanobiotechnology refers to the use of nanotechnology to further the goals of biotechnology. Some of the innovative challenges in the field of biology are: New molecular imaging techniques, Quantitative analytical tools, Physical model of the cell as a machine, Better ex-vivo tests and improvement in current laboratory techniques and Better drug delivery systems.

RelatedBiotechnology Conferences

Track 6:Plant Biotechnology

Plant biotechnology is the technique used to manipulate the plants for specific needs or requirement. In traditional process seed is the major source for germinating a new plant but the advance method is independent that combines multiple needs to get the required traits.Plant biotechnologymeets the challenge that includesgenomics,genetic engineering,tissue culture, andtransgenic cropsetc. These biotechnological applications allow researchers to detect and map genes and discover their functions, selection of specific genes in genetic resources and its breeding and to customize the plant according to the requirement by transferring the genes of specific traits to combine with others to create a new species. The recent advances in plant biotechnology provide potential way to make improvements much more quickly than conventionalplant breedingtechniques. Plant tissue culture is a part of plant biotechnology which is the collection of many techniques that is used to maintain and grow plant, plant cells, plant tissues under controlled sterile conditions over the nutrient medium. Plant tissue culture is the convenient method produce clones of a plant through the process calledmicropropagation. The main advantage of this method is to produce exact and multiple copies of plants with good desired properties like good flowers, fruits and other characters within small span of time. Production of multiple plants without seed, production of genetically modified plants, the tissue culture plants are resistant to the diseases,pathogensand pests, also it is the best method to store the gene pools and many more

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; 3rd CaribbeanBiomedicalResearch Days, January 16-18, 2016, Rodney Bay, Saint Lucia;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; 18th International Conference onAgricultural Biotechnology, Biological and Biosystems Engineering, January 18-19, 2016, London, United Kingdom; 2nd International Conference on Biotechnology andAgriculture EngineeringApril 08-09 2016 in Tokyo, Japan; Food Structures, Digestion andHealth3rd International Conference, 28-30 October 2015, Wellington, New Zealand; 3rd Conference ofCereal Biotechnologyand Breeding, November 2-4, 2015, Berlin, Germany;

Track 7:Agricultural Biotechnology

Agricultural biotechnologyis the area of biotechnology involving applications to agriculture. Agricultural biotechnology has been practiced for a long time, as people have sought to improve agriculturally important organisms by selection and breeding. An example of traditional agricultural biotechnology is the development of disease-resistant wheat varieties by cross-breeding different wheat types until the desired disease resistance was present in a resulting new variety. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding. Whatever the particular technology used, the crops may be destined for use for food,biomaterialsor energy production.Genetic modificationmeans that existing genes are modified or new genes included to give plant varieties desirable characteristics, such as resistance to certain pests or herbicides, or forvitaminfortification. Because only a few genes with known traits are transferred, GM methods are more targeted and faster thantraditional breeding. Biotechnology has helped to increase crop productivity by introducing such qualities as disease resistance and increased drought tolerance to the crops.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; Conference onAgricultural Statistics2015, Sarawak, Malaysia; 2nd International Conference onGlobal Food Security, 11-14 October 2015, Ithaca, United States; 5th International Conference onOrganic AgricultureSciences, 14th-17th October 2015, Bratislava, Slovakia; 18thInternational Conference onAgricultural, Biotechnology, Biological and Biosystems Engineering, January 18-19, 2016, London, United Kingdom; 2nd International Conference on Biotechnology andAgriculture EngineeringApril 08-09 2016 in Tokyo, Japan;Food Structures, Digestion andHealth3rd International Conference, 28-30 October 2015, Wellington, New Zealand; 3rd Conference of Cereal Biotechnology andBreeding, November 2-4, 2015, Berlin, Germany; AdvancedWater TreatmentforFood & Beverage, 3-4 Nov 2015, Amsterdam, Netherlands

Track 8:Environmental Biotechnology

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. The International Society for Environmental Biotechnology defines environmental biotechnology as "the development, use and regulation of biological systems for remediation of contaminated environments (land, air, water), and for environment-friendly processes (green manufacturing technologies and sustainable development)

RelatedBiotechnology Conferences

5th International Conference onBiodiversity, March 10-12, 2016 at Madrid, Spain; International Conference on Biotechnology andEnvironmental ManagementSeptember 14-15 Milan, Italy; 6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; International Conference onGreen Energy& Expo September 21-23, 2015 Orlando, FL, USA; International Conference on Environment,Energy and Biotechnology, May 25, 2016 Jeju Island, Republic of Korea; International Conference on Energy andEnvironmental Biotechnology, November 24 - 25, 2015 Dubai, UAE; Science for theEnvironmentConference 2015, October 1-2 2016 Aarhus, Denmark; International Conference onEnvironmental Scienceand Technology 14th to 17th May 2016, Antalya, Turkey

Track 9:Marine Biotechnology

Marine Biotechnology is a relatively new field of study, having emerged in the past few years. The Marine Biotechnology is intended to host scientific contributions inmarine sciencethat are based on the enormousbiodiversityof marine ecosystems and the genetic uniqueness of marine organisms to develop useful products and applications.Aquaculture& Marine Biotechnology have been the subject of great importance not only because of the sustainable utilization of their resources to feed the billion people of the world but also for the future challenges for discovery of new products and process development of economic importance through its treasure recognition and diversification. Apart from contributing to high quality and healthy food (aquaculture),nutraceuticalsand medicinal products (anti-cancer andantimicrobials), this sector is expected to contribute to sustainable alternative source of energy (biofuelfrom microalgae) and environmental health. Marine Biotechnology is capable of making an important contribution towards meeting impending challenges like a sustainable supply of food and energy and human health.

RelatedBiotechnology Conferences

5th International Conference on Biodiversity, March 10-12, 2016 at Madrid, Spain; International Conference on Biotechnology and Environmental Management September 14-15, Milan, Italy; 6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;BioMarine2015, 12-14 Oct 2016, Wilmington, NC, United States; International Conference onMarine BiotechnologyandBioprocessing, December 10 - 11, 2015, Sydney, Australia; Annual world congress ofMarine Biotechnology-2015, November 6-8 2015, Qingdao, China;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; Annual InternationalMarine BiotechnologyConference, Nov 20, 2013, Brisbane, Australia

Track 10:Current Scenario of Biotechnology

Due to multidisciplinary nature of the field of biotechnology, a wide range of different branches of science have made significant contributions to the fast development of this field. Some of these disciplines are-biochemical engineering,physiology,biochemistry,food science,material science,bioinformatics,immunology,molecular biology,chemical engineeringetc. Biotechnology is also improving the lives of people around the world. Biotechnology also has affected economy in a positive way due to the creation and growth of small business, generation of new jobs. Agricultural biotechnology has reduced our dependency on pesticides.Bioremediation technologiesare being used to clean our environment by removing toxic substances from contaminated ground water and soils. about 60% of the biotechnology products in the market are healthcare products and 21% are products used in agriculture andanimal husbandry. A considerable amount of efforts in research are on, to use and extract benefit from this interesting and upcoming field for the betterment of human life and the environment. Many biochemical companies are involved in the production of biotechnological products usinggenetic engineeringtechniques.

RelatedBiotechnology Conferences

Track 11:Animal Biotechnology

Biotechnology provides new tools for improvinghuman healthand animal health and welfare and increasinglivestock productivity. Biotechnology improves the food we eat-meat, milk and eggs. Biotechnology can improve an animals impact on the environment. And biotechnology enhances ability to detect, treat and prevent diseases. Just like other assistedreproduction techniquessuch asartificial insemination,embryo transferandin vitro fertilization, livestockcloningimproves animal breeding programs allowing farmers and ranchers to produce healthier offspring, and therefore producer healthier, safer and higher quality foods more consistently.

RelatedBiotechnology Conferences|Biotechnology Events|Biochemistry Conferences

Track 12:Biomass and Bioenergy

Bioenergyis the chemical energy contained in organic matter (biomass) which can be converted into energy forms that we can use directly, such as electricity, heat and liquid fuel. Biomass is any organic matter of recently living plant or animal origin. Unlike coal, the organic matter is notfossilised.Bioenergy plantscan range from small domestic heating systems to multi-megawatt industrial plants requiring hundreds of thousands of tonnes ofbiomassfuel each year. A variety of technologies exists to release and use the energy contained in biomass. They range from combustion technologies that are well proven and widely used around the world for generating electricity generation, to emerging technologies that convert biomass intoliquid fuelsfor road, sea and air transport.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; IEABioenergyConference 2016, October 26th-29th2016, Berlin, Germany; Summit onIndustrial biotechnologyandBioenergy, December 7 -9, 2016 San Diego, California; Energy Conference, Des Moines, Oct 13-15 Iowa, USA; EuropeanBiomassConference and Exhibition Amsterdam, 6-9, June, Germany Netherlands; EcoSummit 2016, August 29 - September 01 2016, Montpellier, France; InternationalBioenergyand Bioproducts Conference, October 28-30, 2016 Atlanta, Georgia; 2016 InternationalBiomassConference & Expo, Charlotte, North Carolina;World Bioenergy2016, May 24-26 2016, Stockholm, Sweden; 2016 InternationalFuel EthanolWorkshop & Expo, June 20-23, 2016 Milwaukee, Wisconsin.

Track 13:Biotechnology and its Applications

The applications of biotechnology are so broad, and the advantages so compelling, that virtually every industry is using this technology. Developments are underway in areas as diverse aspharmaceuticals, diagnostics,textiles,aquaculture,forestry, chemicals, household products,environmental cleanup,food processingand forensics to name a few. Biotechnology is enabling these industries to make new or better products, often with greater speed, efficiency and flexibility. Biotechnology holds significant promise to the future but certain amount of risk is associated with any area.

RelatedBiotechnology Conferences

Track 14:Biotechnology Market

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2017 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2017 and reach a value worth USD 414.5 billion by the end of 2017. This market was valued approximately USD 216.5 billion in 2011. The market of bioagriculture, combined with that of bioseeds, is projected to reach a value worthUSD 27.46 billionby 2018. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

RelatedBiotechnology Conferences

Track 15: Biotech Companies and Market Analysis

The biotechnology community in Europe has seen significant growth in recent years. By establishing itself in several key niche markets, the European biotech and pharma industries have thrived in the global biopharmaceutical market. Europe high standards for their life science educational systems have increased the level of growth and the quality of Europes workforce and broadened Europes reach within the world. With a dedication to innovation and research, Europe has established itself as a leader in biotechnology.

RelatedBiotechnology Conferences

Track 16: Biotech Startups and Funding:

Biotechnology being an emerging industry, game-changing strategies and relevant application of the knowledge-intelligence resource pool, drive the process of growth. Europe Biotechnology seeks to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the industry by offering a vibrant global platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research institutions, investors, service providers, policy makers, regulators and analysts.

RelatedBiotechnology Conferences

Track 17: Advances in Biotech Manufacturing

The biotechnology community in Asia has seen significant growth in recent years. By establishing itself in several key niche markets, the European biotech and pharma industries have thrived in the global biopharmaceutical market. Asias high standards for their life science educational systems have increased the level of growth and the quality of Asias workforce and broadened Asias reach within the world. With a dedication to innovation and research, Asia has established itself as a leader in biotechnology.

RelatedBiotechnology Conferences

Track 18: Biotech Investors and Grants

The biotechnology industry hauled in $2.3 billion worth of venture capital investments during the second quarter of this yeara 32% increase over the prior quarter, according to the newest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters. The 126 deals struck during the period marked the biggest quarterly investment in biotech since the MoneyTree report first came out in 1995, and it brought the total for the first half to $3.8 billion.

RelatedBiotechnology Conferences

8th Euro Biotechnology Congress (Euro Biotechnology-2015) was held during August 18-20, 2015 at Flemings Conference Hotel, Frankfurt, Germany. The conference was marked with the attendance of Editorial Board Members of supported OMICS Group Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 30 countries, who made this conference fruitful and productive.

This conference was based on the theme Biotechnology for a Better Tomorrow which included the following scientific tracks:

Biotechnology in Health Care Environmental Biotechnology Industrial Aspects of Biotechnology Stem Cells and Regenerative Medicine Marine Biotechnology and Aquaculture Agriculture Biotechnology Animal Biotechnology Food and Bio Process Biotechnology Cell and Molecular Biology Nanobiotechnology Genetic Engineering and rDNA Technology Current Scenarios and other allied areas of Biotechnology

We are thankful to our below Honourable guests and Keynote Speakers for their generous support and suggestions.

Manfred T Reetz Philipps-University, Germany

W Tim Miller - Echelon-Frontier Scientific Inc, USA

Wilfried Schwab - Technische Universitt Mnchen, Germany

Aline Zimmer- Merck Millipore, Germany

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following topics were highlighted as Keynote-presentations:

Increasing the efficiency of directed evolution of enzymes: Manfred T Reetz, Philipps-University of Marburg, Germany

Trade secrets and laboratory security: Frontier Scientific Inc, USA

Aroma glucoside production: Wilfried Schwab, Technische Universitt Mnchen, Germany

Chemically modified cysteine in fed-batch processes and impact on CHO specific productivity: Aline Zimmer, Merck Millipore, USA

Synthetic mRNAs present a rapidly growing technology: Optimized tool for stem cell generation and for manipulating cellular phenotypes : Guido Krupp, Amptec GmbH, Germany

Novel synthetic anti-microbial defensins through confrontational selection and screening of yeast libraries: K Yankulov, University of Guelph, Canada

Long acting recombinant glycoprotein hormones: From bench to clinics, Fuad Fares, University of Haifa, Israel

Poster Session was judged by K Yankulov, University of Guelph, Canada

The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Euro Biotechnology-2015. We are glad to inform that all accepted abstracts for the conference have been published in OMICS Group Journal of Biotechnology & Biomaterials as a special issue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference, OMICS Group would like to announce the commencement of the 11th Euro Biotechnology Congress" to be held during November 07-09, 2016 at Alicante, Spain

Let us meet Again @ Euro Biotechnology-2016

Biotechnology-2014

OMICS Group Conferencessuccessfully hosted its premier5thWorld Congress on Biotechnologyduring June25-27, 2014 Valencia Conference centre, Valencia Spain

This World congress was accomplished by the support of European Biotechnology Thematic Network Association (EBTNA), Valencia Bioregion (BIOVAL), Federation of Spanish Biotechnologist (FEBiotec) and Societ Italo-Latinoamericana di Etnomedicina (SILAE). Biotechnology-2014 marked with the attendance of Editorial Board Members of supported OMICS Group Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference fruitful and productive.

This5thWorld Congress on Biotechnologywas based on the theme the theme Biotechnology: Meeting the Needs of a Changing World which has covered the below scientific sessions:

The conference was greeted by the welcome message ofProf. Cheorl-Ho KimSung Kyun Kwan University, Korea and moderated byProf. Martin J. DSouza, Mercer University, USA. The support was extended by the below honourable guest Em. Prof.Marc Van Montagu, (World Food Laureate 2013) University of Gent, Belgium, Prof.Roberto Gaxiola, Arizona State University, USA, Prof.Ara Kanekanian, Cardiff Metropolitan University, UK, Prof.Manuel P. Alonso,University of Valencia, Spain, Prof.Cheorl-H. Kim,Sung Kyun Kwan University,Dr. Srinubabu Gedela, OMICS Group Inc, USA and below keynote lectures:

OMICS GroupInternational acknowledge the support of below Chairs and Co-chairs foe whom we were able to run smoothly the scientific sessions includes: Alain Goossens, Ghent University, Belgium, Oscar Vicente, IBMCP, Polytechnic University of Valencia, Spain, Ara Kanekanian, Cardiff Metropolitan University, UK, Ana M. Hortigela, Instituto de Medicina Genmica, Spain, Cheorl-H Kim, Sung Kyun Kwan University, Korea, Martin J. DSouza, Mercer University, USA, Marina V. Frontasyeva, Joint Institute for Nuclear Research, Russian Federation, Zlatka Alexieva, Bulgarian Academy of Sciences, Bulgaria, Salvador Ventura, Universitat Autnoma de Barcelona, Spain, Giuseppe Manco, Institute of Protein Biochemistry, National Research Council (CNR), Italy, Aihua Liu, Qingdao Institute of Bioenergy & Bioprocess, CAS, China, Amparo Pascual-Ahuir Giner, Universidad Politecnica de Valencia, Spain.

Visit link:
Euro Biotechnology Congress

Posted in Biotechnology | Comments Off

Orthopedic Stem Cell Treatments – Orthopedics – Stem Cell …

Posted: September 15, 2016 at 9:43 am

Orthopedic injuries and degenerative joint diseases are some of the most common conditions which cause discomfort and disability. Arthritis ,and the trauma which leads to loss of cartilage and injured tendons and ligaments from sports is common among athletes.

There are many procedures which have been tried with various success rates, ranging from micro fracture to stimulate cartilage growth and Platelet Rich Plasma Injections to strengthen ligaments and tendons. Our study of the use of SVF which contains the stem cells is underway for many of these conditions.

The use of stem cell therapy in Orthopedics is one of the most studied use world wide. Here at the Hawaii Stem Cell Treatment Center we use the stem cell broth of Stromal Vascular Fraction (SVF) and deploy that to the area of concern. This may be the knees , elbows, shoulders, hands, hips or spine.

The deployment is carried out in our center which maintains the highest standards of sterility by using our networks patented closed system of deployment. There is minimal manipulation during the harvesting and processing of the SVF which comes from your own fat. For certain areas such as the hip or spine we may make use of imaging to assure exact placement of the SVF.

Additionally we use other specialist such as invasive radiologist and orthopedic specialist in many cases to carry out this deployment. Our network uses the same orthopedic protocols and maintains an extensive shared data base in which your data will be entered if accepted in these research protocols.

Posted in Hawaii Stem Cells | Comments Off

Stem Cells | Topics | Christianity Today

Posted: September 13, 2016 at 11:46 pm

(UPDATED) ALS raises $100 million in 30 days; pro-life groups worry about embryonic research.

Morgan Lee / August 29, 2014

Biotech advances could make destroying human embryos for research a relic of the past.

Bob Smietana / November 22, 2013

Human cells have been resistant to cloninguntil now.

Christine A. Scheller / May 15, 2013

The new executive director at the Center for Bioethics and Human Dignity discusses recent bioethical debates.

Interview by Alicia Cohn / July 23, 2009

Access to federal money may be mixed blessing for embryonic research.

Sarah Pulliam / April 23, 2009

Why scientific breakthroughs make the destruction of human embryos obsolete.

Rep. Mike Pence / March 23, 2009

When science is made 'apolitical' and 'unencumbered by religion,' it's usually to hyper-politicize and hyper-sacralize it.

Mollie Ziegler Hemingway / March 23, 2009

Where the parties stand on abortion, faith-based programs, religious liberty, and other issues.

August 27, 2008

All three candidates have voted to fund embryonic stem-cell research.

Sarah Eekhoff Zylstra / April 9, 2008

Advances in stem-cell technology cheer and alarm ethics watchers.

Sarah Eekhoff Zylstra / November 16, 2007

Plus: Surgeon general nominee's Methodist work under fire, Time interviews Rowan Williams, church building conflicts, and other stories from online sources around the world.

Compiled by Ted Olsen / June 8, 2007

Why we struggle to gain our moral footing in bioethics.

A Christianity Today Editorial / March 1, 2007

Research advance could shift stem-cell debate.

Sarah Pulliam / February 12, 2007

Fear of mortality lies at the root of our bioethics confusion.

A Christianity Today Editorial / January 2, 2007

It's hard to see the humanity of tiny embryos if we live by blind faith.

Stan Guthrie / November 9, 2006

Embryonic stem cells factor in the race for Henry Hyde's U.S. House seat.

Collin Hansen / November 2, 2006

A new statement from Evangelicals and Catholics Together encourages discourse on the most divisive of issues.

David Neff / October 10, 2006

Plus: Prolifers rally and ... burn the Qur'an?! On having Ralph Reed to kick around, banning baths, and a bunch of links to a bunch of other stories.

Compiled by CT staff / July 21, 2006

Plus: The latest from the Korean cloning scandal.

Nigel M. de S. Cameron / April 27, 2006

The "anti-Genesis" of those who play God, and why the biotech business needs to take ethics seriously.

Nigel M. de S. Cameron / April 19, 2006

Tomorrow's "godlike massively intelligent machines." Plus: Our nanotech future and some good news on stem cells that really work.

Nigel M. de S. Cameron / April 12, 2006

Plus: Good news from Europe on stem-cell funding.

Nigel M. de S. Cameron / April 5, 2006

Plus: The latest on the biopolicy agenda and some outrageous lies on stem cells.

Nigel M. de S. Cameron / March 30, 2006

The U.K. and disaffected American researchers lash out at U.S. cloning laws.

Nigel M. de S. Cameron / March 17, 2006

How to sell unethical science.

Nigel M. de S. Cameron / March 2, 2006

The latest sad story from the Korean soap operaand a lack of Talent in Missouri.

Nigel M. de S. Cameron / February 17, 2006

President Bush sets out a vital agenda for ethics.

Nigel M. de S. Cameron / February 2, 2006

From the frying pan into the fire.

Nigel M. de S. Cameron / January 20, 2006

C. S. Lewis was way ahead of the curve.

by Nigel M. de S. Cameron / November 30, 2005

And they may end up in a laboratory near you.

by Nigel M. de S. Cameron / November 2, 2005

What Americans really think about science: astonishing new polling data.

by Nigel M. de S. Cameron / October 26, 2005

The Majority Leader's contradictions mirror the opinions of the public at large.

by Nigel M. de S. Cameron / October 11, 2005

Remember Prop. 71? Stem-cell research supporters hope voters don't remember the promises they made.

by Nigel M. de S. Cameron / October 5, 2005

The little-known story of the stem cells that actually work.

David A. Prentice / September 30, 2005

What does it mean when even embryonic stem-cell researchers have some qualms about their work?

by Christine A. Scheller / September 29, 2005

Pro-lifers face a scientific and public relations juggernaut.

by Stan Guthrie with Agnieszka Tennant, Sheryl Henderson Blunt in Washington, and Rob James in the United Kingdom / September 28, 2005

The man who led the President's Council on Bioethics brought protests from the industry and directed groundbreaking studies.

by Nigel M. de S. Cameron / September 21, 2005

The Washington Post muddles a major breakthrough in adult stem-cell research, while the U.K. marches blindly on.

by Nigel M. de S. Cameron / August 29, 2005

Introducing our new life ethics weblog.

by Nigel M. de S. Cameron / August 10, 2005

Killing human embryos for research is not pro-life.

by Stan Guthrie / August 2, 2005

Read this article:
Stem Cells | Topics | Christianity Today

Posted in Missouri Stem Cells | Comments Off

Monthly Archives: September 2016

Non-Small Cell Lung Cancer Treatment (PDQ)Health …

Stem Cell Treatment Center Hawaii – Stem Cell Treatment …

Minnesota to resume umbilical cord blood donations …

University of Michigan Stem Cell Research | Experts List

Stem Cells for Orthopedics Missouri & Florida

Stem Cells Quotes – Notable Quotes

Cells Harvested From Human Urine Used to Make Stem Cells

Euro Biotechnology Congress

Orthopedic Stem Cell Treatments – Orthopedics – Stem Cell …

Stem Cells | Topics | Christianity Today

Categories

Archives

Recommended Sites

Contact Us

Recent Posts